These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36322407)

  • 41. Amplification of 7p12 Is Associated with Pathologic Nonresponse to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Pichler R; Lindner AK; Compérat E; Obrist P; Schäfer G; Todenhöfer T; Horninger W; Culig Z; Untergasser G
    Am J Pathol; 2020 Feb; 190(2):442-452. PubMed ID: 31843500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
    Beckabir W; Zhou M; Lee JS; Vensko SP; Woodcock MG; Wang HH; Wobker SE; Atassi G; Wilkinson AD; Fowler K; Flick LM; Damrauer JS; Harrison MR; McKinnon KP; Rose TL; Milowsky MI; Serody JS; Kim WY; Vincent BG
    Nat Commun; 2024 May; 15(1):4448. PubMed ID: 38789460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients.
    Laviana AA; Schiftan EG; Mashni JW; Large MC; Kaimakliotis HZ; Nolte DD; Turek JJ; An R; Morgan TA; Chang SS
    Urol Oncol; 2023 Jun; 41(6):295.e9-295.e17. PubMed ID: 36522279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
    Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
    Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
    [No Abstract]   [Full Text] [Related]  

  • 46. Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Font A; Domenech M; Buisan O; Lopez H; González A; Etxaniz O; Matas M; Elias X; Gomez M; Figols M; Horneros J; Pardo JC; Notario L; Ruiz de Porras V; Perez I; Areal J; Esteve A
    World J Urol; 2022 Nov; 40(11):2627-2634. PubMed ID: 36107212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.
    Olah C; Hahnen C; Nagy N; Musial J; Varadi M; Nyiro G; Gyorffy B; Hadaschik B; Rawitzer J; Ting S; Sjödahl G; Hoffmann MJ; Reis H; Szarvas T
    Int J Cancer; 2022 Mar; 150(5):856-867. PubMed ID: 34536301
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Wang Y; Song Y; Qin C; Zhang C; Du Y; Xu T
    Ann Med; 2023; 55(2):2281654. PubMed ID: 37963224
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019.
    Körner SK; Jensen JB
    Scand J Urol; 2022 Feb; 56(1):34-38. PubMed ID: 34775886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. microRNA expression profiles as decision-making biomarkers in the management of bladder cancer.
    Amir S; Mabjeesh NJ
    Histol Histopathol; 2017 Feb; 32(2):107-119. PubMed ID: 27586262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
    Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
    J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
    World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.
    Mir MC; Marchioni M; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; McGrath JS; Kassouf W; Dall'Era MA; Sridhar SS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand D; Black PC
    Eur Urol Focus; 2021 Nov; 7(6):1347-1354. PubMed ID: 32771446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective.
    Kim JM; Choi E; Sung SH; Jo J; Lee DH; Park S
    Clin Genitourin Cancer; 2024 Apr; 22(2):224-236. PubMed ID: 38042728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Miron B; Hoffman-Censits JH; Anari F; O'Neill J; Geynisman DM; Zibelman MR; Kutikov A; Viterbo R; Greenberg RE; Chen D; Lallas CD; Trabulsi EJ; Alpaugh RK; Dulaimi E; Golemis EA; Uzzo R; Ross EA; Plimack ER
    Eur Urol Oncol; 2020 Aug; 3(4):544-547. PubMed ID: 32165095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.